Empa ACC Expert Consensus Decision Pathway

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news